Acadia advances care for underserved neurological disorders and rare diseases. Since its founding, the company has been working at the forefront of healthcare to bring vital solutions to people who need them most.
The company is dedicated to turning scientific promise into meaningful innovation, with a focus on areas where patients have few or no treatment options, such as Parkinson’s Disease Psychosis, Rett Syndrome, and Alzheimer’s Disease Psychosis.
Acadia is committed to patient-centered values, driven by the needs of those affected, and advances therapies through bold science, collaboration, and enduring leadership.
